News in Gastric Cancer

News from around the world, curated by the Gastric Cancer Foundation.

Positive Results For Ramucirumab as Single Agent in Phase III Gastric Cancer Trial

Eli Lilly announced that the REGARD trial, a Phase III study of ramucirumab (IMC-1121B) in patients with metastatic gastric cancer, met its primary endpoint of improved overall survival and also showed prolonged progression-free survival. This trial is the first Phase III data read-out for ramucirumab.

X